Akura Medical Receives FDA Approval for Groundbreaking Study
Akura Medical is transforming the landscape of venous thromboembolism (VTE) treatment with a pivotal development in pulmonary embolism (PE) care. The FDA has granted approval for the company to initiate the QUADRA-PE study, which will assess the efficacy and safety of the innovative Katana™ Thrombectomy System in patients suffering from acute pulmonary embolism. This crucial study aims to address a significant medical challenge that affects countless individuals.
Understanding the QUADRA-PE Study
The QUADRA-PE study is a meticulously designed international trial set to enroll up to 118 patients at approximately 26 leading medical institutions. The research will focus on determining the effectiveness of the Katana System by measuring the reduction in the right ventricular-to-left ventricular (RV/LV) ratio within the initial 48 hours post-procedure, as evaluated through CT angiography. Additionally, it aims to ensure patient safety by monitoring any major adverse events occurring within the same timeframe.
What Makes the Katana™ Thrombectomy System Unique?
The Katana System is distinguished by its thoughtfully engineered features, designed to enhance the experience for both physicians and patients. These include a bi-directional, low-profile sheath optimized for navigating complex vascular pathways, and high-velocity saline jets intended to disrupt clots irrespective of their morphology while minimizing the risk of catheter clogging.
Real-Time Insights for Enhanced Procedures
One of the impressive elements of the Katana System is the incorporation of sensors capable of providing real-time pulmonary artery pressure data. This vital information allows healthcare professionals to gain insights into the progress of the procedure, potentially reducing uncertainty and elevating patient outcomes. Complemented by the Sentinel™ console, which monitors clot engagement and blood loss, the system aims to empower physicians in their decision-making processes.
The Urgency of Addressing Pulmonary Embolism
Pulmonary embolism is a grave medical condition characterized by a blood clot obstructing blood flow to the lungs. This condition can rapidly become life-threatening, making immediate action vital. In the United States alone, acute PE is attributed as the third leading cause of cardiovascular mortality, impacting nearly 900,000 individuals each year. Alarmingly, statistics reveal that approximately 10-30% of these patients may succumb within one month of diagnosis, highlighting the urgent need for effective interventions.
About Akura Medical, Inc.
Akura Medical, a privately held innovation-driven company, operates under the Shifamed portfolio, specializing in medical technology aimed at advancing treatments in the realm of VTE. Their flagship product, the Katana™ Thrombectomy System is designed to redefine standards for managing pulmonary embolism. Akura Medical embodies a commitment to reshaping VTE care and fostering better patient outcomes globally.
About Shifamed, LLC
Under the direction of the visionary entrepreneur Amr Salahieh, Shifamed serves as a dedicated medical innovation hub. Their mission is to create conditions that foster rapid market readiness, mitigate risks, and amplify the impact of medical solutions, all while promoting longer, healthier lives for patients.
Frequently Asked Questions
What is the focus of the QUADRA-PE study?
The QUADRA-PE study evaluates the safety and effectiveness of the Katana™ Thrombectomy System for treating patients with acute pulmonary embolism.
How many patients are expected to participate in the trial?
Up to 118 patients will be enrolled across approximately 26 medical institutions worldwide.
What are the key measurements for success in the study?
The primary effectiveness endpoint is the reduction of the RV/LV ratio within 48 hours post-procedure, assessed using CT angiography.
What makes the Katana System unique?
The Katana System features advanced engineering that minimizes catheter clogging and provides real-time insights during procedures.
Why is addressing pulmonary embolism critical?
Pulmonary embolism is a serious condition and is the third leading cause of cardiovascular death in the U.S., emphasizing the necessity for effective treatment options.
